Early Stage: Step 5 - Forming the entity ( Editor's note: This is the fifth in a ...)

Early Stage: Step 5 - Forming the entity

Editor's note: This is the fifth in a series of articles on developing start-up companies in the technology or biotechnology sectors.

Madison, Wis. - By now you have clarified what your intellectual property is - the domain name, trademarks, etcetera. You are now prepared to form an entity. In this column, we will discuss the entity choices yo......

Full article >>>

Source:wistechnology.com By Joe Boucher 01/27/07

Page: 1 2 3 4
Related biology technology :

1. Early Stage: Step 11 - Other forms of finance
2. Early Stage 10: The nuances of federal laws
3. Early Stage, Step 9: Raising capital in the securities landscape
4. Early Stage, Step 8: Misclassifying workers brings risk
5. Early Stage 7, Part I: Just what is an employee?
6. Early Stage: Step 6 - Taxes, taxes, taxes!
7. Early Stage, Step 4: Cautionary trademark tales
8. Early Stage, Step 3: Naming the entity
9. Early-stage quality brings investment, Meier says
10. Early-stage executives hear from investors
11. Early Stage Step 2: Choosing a domain name

Post Your Comments:

(Date:11/6/2009)...PRNewswire-FirstCall/ -- BioSpecifics Technologies...ny developing first-in-class collagenase-based pro...he third quarter ended September 30, 2009. ,, ...s year, the FDA,s Arthritis Advisory Committee una...val of XIAFLEX(TM) for the treatment of Dupuytren,...

(Date:11/6/2009)...ov. 6 Calbiotech, Inc. announced t...ovative Research (SBIR) Phase I contract by the U....er terms of the agreement, Calbiotech will develop...s of Dengue virus. ,, Dengue virus is a mosq...t to military forces deployed to tropical areas of...

(Date:11/5/2009)...5 GenVec, Inc. (Nasdaq: ...the third quarter ended September 30, 2009. GenVec...are) for the three months ended September 30, 2009... share) in the comparable quarter of 2008. For the...t loss was $14.1 million ($0.15 per share), compar...

(Date:11/5/2009)...day, November 5, 2009 at 4:30 p.m. Eastern Time ,...FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("Onc...eported unaudited financial results for the third ...nd reviewed the Company,s highlights for the third... results reflect the operations of OncoGenex Techn...

[0] Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results [0] Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus [0] GenVec Reports Third Quarter 2009 Financial Results [0] OncoGenex Reports Third Quarter 2009 Financial Results

...s., Oct. 31 Idenix,Pharmaceuticals, Inc., (Nasdaq...financial results for the third quarter of 2007 on... markets close. In conjunction with the issuance ...a conference call at 4:30 p.m. ET on Tuesday, Nove...sults for the third quarter,2007. To access the c...

...ct. 31 Modigene Inc. (OTC,Bulletin Board: MODG) t...,at the Acumen BioFin Rodman & Renshaw 9th Annual ...07 at 1:40 pm ET. The conference will be held at,t...ne CEO Abraham Havron and President Shai Novik wil...ew and review of corporate,developments. The pres...

.... 31 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS )...n,BioFin(TM) Rodman & Renshaw 9th Annual Healthcar...p.m. EST (1:25 p.m. PST). The conference is being,... Ph.D., President and Chief Executive Officer of A...ew of Anadys and its two,development-stage product...

Other Biology Technology:Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2 Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference 2

Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference

(Date:11/4/2009)...,, CARLSBAD, Calif., Oct. 23 Ge...ure biosample management for genomic discovery, me...vid Wellis, Ph.D., GenVault,s President and CEO, w...e taking place on October 26th and 27th in La Joll...ill provide an overview of the company together wi...

(Date:11/4/2009)...,, NEW YORK, Oct. 27 Global Rai...mpany and advanced R&D laboratory, today annou...e and is prepared to actively commercialize its su...dge biometric security offerings. ,, During the...llions of dollars to develop and deploy a series o...

(Date:11/4/2009)...,, CARLSBAD, Calif., Nov. 4 Gen...hat William Brody, M.D., Ph.D., has joined its Boa...idential Chair of the Salk Institute, is an acclai...ior to joining the Salk Institute, Dr. Brody serve...e is a member of the National Academy of Engineeri...

Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2 Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2 Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3 Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2 Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3 Secretary Shinseki Moves to Simplify PTSD Compensation Rules 55136 1 Secretary Shinseki Moves to Simplify PTSD Compensation Rules 55136 2 Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 1 Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 2 Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 3 Grammy 28R 29 Nominated R 26B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African Americans to be Victorious in 55133 4 IDEV 28R 29 Technologies Announces First Patient Enrolled in Multi Center Clinical Trial of SUPERA 28R 29 PERipheral Stent 4886 1 IDEV 28R 29 Technologies Announces First Patient Enrolled in Multi Center Clinical Trial of SUPERA 28R 29 PERipheral Stent 4886 2

[0] GenVault Corporation to Present at the 2009 BIOCOM Investor Conference [0] Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality [0] Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors

...mall molecules containing platinum, Virginia Commo...s have created a process to inhibit a class of pro...may help researchers develop new drugs to fight HI...n as zinc fingers. , In the May 30 issue of the j...ed that a zinc finger protein, known as HIV NCp7, ...

...earcher Zafira Castaño has discovered that the los...favors tumor growth. This was the conclusion that ...tion which she defended at the University of Navar...h prior studies from her laboratory, which demonst...cells that coat the normal lung, and which, nevert...

...ty crayfish - a voracious, bullying exotic that ha...akes - may have finally met its match. , Since it... 1950s, the crayfish has spread to thousands of la...sts that are critical fish habitat, evicting the n...r and scooping up fish eggs like so much caviar. ...

Other Biology News:New protein target may advance design of HIV and cancer drugs 2 Study shows hope for ridding lakes of clawed invader 2 Study shows hope for ridding lakes of clawed invader 3

New protein target may advance design of HIV and cancer drugs The loss of a protein favors lung tumor growth Study shows hope for ridding lakes of clawed invader

Mycoplasma IgG ELISA Kit, Single from Bio-Quant Inc.

Methadone ELISA Kit, Single from Bio-Quant Inc.

Rat Prolactin EIA Kit from Cayman Chemical

Z Amphetamine ELISA Kit, Single from Bio-Quant Inc.

Biology Products:

Mycoplasma IgG ELISA Kit, Single from Bio-Quant Inc.Methadone ELISA Kit, Single from Bio-Quant Inc.Rat Prolactin EIA Kit from Cayman Chemical Z Amphetamine ELISA Kit, Single from Bio-Quant Inc.

( Editor's note: This is the fifth in a ...)Early Stage: Step 5 - Forming the entity